GenSight Biologics (SIGHT) Q1 2026 TU earnings summary

Executive summary

• Cash and cash equivalents were €3.2 million at March 31, 2026, versus €2.4 million at December 31, 2025; March early-access proceeds were €2.6 million.

• Management expects 2026 paid early-access program revenues to cover operating expenses, excluding costs of the Phase III RECOVER study and certain related manufacturing costs.

Financial highlights

• Q1 2026 operating cash burn mainly reflected preparation and management of GS010 early-access programs, primarily in France, and preparation for the Phase III RECOVER study.

• The first €2.6 million of proceeds from the French Named Patient Early Access Program was recorded in March 2026.

Outlook and guidance

• Aggregate revenues from paid early-access programs in 2026 are expected to cover operating expenses for the year, excluding RECOVER trial costs and certain study-related manufacturing costs.

• Treatment and payment timing remains uncertain; additional French treatments are scheduled for April, and the paid Named Patient Program in Israel is expected to begin in Q2 2026.

• The French AAC treatment price is €425,000 per injection.